In the claims:

1. (Previously Presented) A method of treatment of atherosclerosis, cerebrovascular disease, peripheral vascular disease, stenosis, restenosis and/or in-stent-stenosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound, said compound selected from the group having a formula:



or pharmaceutically acceptable salts thereof, wherein:

(i) A_1 and A_2 are each independently selected from the group consisting of CH_2 and C=O, at least one of A_1 and A_2 being CH_2;

(ii) R_1 and R_2 are each independently selected from the group consisting of an alkyl chain having 1-27 carbon atoms and



wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:

 , -OH, –H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups; and

Z is selected from the group consisting of:

 and –OH,

whereas R_4 is an alkyl,

at least one of R_1 and R_2 being said 

; and

(iii) R_3 is selected from the group consisting of H, acyl, alkyl, phosphocholine, phosphoethanolamine, phosphoserine, phosphocardiolipin and phosphoinisitol.

2. (Original) The method of claim 1, wherein each of A_1 and A_2 is CH_2.

3. (Original) The method of claim 1, wherein R_1 is an alkyl chain having 1-27 carbon atoms and R_2 is



wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:



, -OH, –H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups; and

Z is selected from the group consisting of:



and –OH,

whereas R_4 is an alkyl.

4. (Original) The method of claim 3, wherein each of A_1 and A_2 is CH_2.

5. (Original) The method of claim 1, wherein said compound is administered via mucosal administration.

6. (Original) The method of claim 1, wherein administration of said compound is nasal, oral or intra- peritoneal administration.

7. (Original) The method of claim 1, wherein administration of said compound reduces immune reactivity to oxidized LDL in said subject.

8. (Currently Amended) The method of claim 1, wherein said compound is administered in addition to a therapeutically effective amount of at least one ~~additional compound selected from the group consisting of~~ statins~~, mucosal adjuvants, corticosteroids, anti-inflammatory compounds, analgesics, growth factors, toxins, and additional tolerizing antigens~~.

9-19. (Canceled)

20. (Previously Presented) A method of treatment of atherosclerosis, cardiovascular disease, cerebrovascular disease, peripheral vascular disease, stenosis, restenosis and/or in-stent-stenosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound, said compound selected from the group having a formula:



or pharmaceutically acceptable salts thereof, wherein:

(i) A_1 and A_2 are each independently selected from the group consisting of CH_2 and C=O, at least one of A_1 and A_2 being CH_2;

(ii) R_1 is selected from the group consisting of an alkyl chain having 1-27 carbon atoms and



wherein X is an alkyl chain having 1-24 carbon atoms,

Y is selected from the group consisting of:

 , -OH, –H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups; and

Z is selected from the group consisting of:

 and –OH,

whereas R_4 is an alkyl;

(iii) R_2 is



wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:

 , -OH, –H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups; and

Z is selected from the group consisting of:

 and –OH,

whereas R_4 is an alkyl; and

(iv) R_3 is selected from the group consisting of H, acyl, alkyl, phosphocholine, phosphoethanolamine, phosphoserine, phosphocardiolipin and phosphoinositol.

21. (Previously Presented) The method of claim 20, wherein each of A_1 and A_2 is CH_2.

22. (Previously Presented) The method of claim 20, wherein R_1 is an alkyl chain having 1-27 carbon atoms and R_2 is



wherein X is an alkyl chain having 1-24 carbon atoms, Y is selected from the group consisting of:



, -OH, –H, alkyl, alkoxy halogen, acetoxy and aromatic functional groups; and

Z is selected from the group consisting of:



and –OH,

whereas R_4 is an alkyl.

23. (Previously Presented) The method of claim 22, wherein each of A_1 and A_2 is CH_2.

24. (Previously Presented) The method of claim 20, wherein said compound is administered via mucosal administration.

25. (Previously Presented) The method of claim 20, wherein administration of said compound is nasal, oral or intra- peritoneal administration.

26. (Previously Presented) The method of claim 20, wherein administration of said compound reduces immune reactivity to oxidized LDL in said subject.

27. (Currently Amended) The method of claim 20, wherein said compound is administered in addition to a therapeutically effective amount of at least one ~~additional compound selected from the group consisting of~~ statins~~, mucosal adjuvants, corticosteroids, anti-inflammatory compounds, analgesics, growth factors, toxins, and additional tolerizing antigens~~.